Intellect Neurosciences Inc. (fka ILNS)

[montanus]

PFE/RINAT (RN6G) and AMD

"Pfizer is committed to developing novel therapies that improve the lives of patients with ophthalmic diseases. Our in-line medicines in this area include Xalatan® (latanoprost ophthalmic solution), Xalacom® (latanoprost and timolol), and Macugen® (pegaptanib injection). Within Pfizer an Ophthalmology forum exists to align several research units under WRD leadership. WRD established the Ophthalmology External Research Unit (OERU) to lead this effort. The OERU utilizes a virtual biotech model to build its portfolio through shared-risk partnerships leveraging the combined scientific, development, and commercial expertise of Pfizer and its partners. The OERU's alliance with Lpath, Inc. to develop and commercialize iSONEP®, which is being evaluated for the treatment of wet age-related macular degeneration and other ophthalmology disorders, is an excellent example of this innovative collaborative approach. The other units focusing on Ophthalmology within WRD are Rinat and Neusentis. Rinat focuses on a monoclonal antibody approach for the treatment of ophthalmic disease. Within this unit RN6G, a monoclonal antibody targeting amyloid beta peptides, is being tested in a clinical trial for use in dry AMD and Geographic Atrophy. The Neusentis unit within WRD is at the forefront of stem cell technology and is studying its use for wet AMD."
http://www.pfizer.com/partnering/areas_of_interest/ophthalmology

Last RN6G study was terminated in feb. 2016 and ILNS restarted (March 30, 2016) their CONJUMAB AMD programm after that, very interesting!
https://clinicaltrials.gov/ct2/show/NCT01577381?term=rn6g&rank=3
http://www.marketwired.com/press-release/intellect-neurosciences-inc-engages-benjamin-d-freilich-md-facs-as-senior-medical-affairs-otcqb-ilns-2110268.htm


About conjumab:

"Our lead program, CONJUMAB-A, offers an important advantage to the Aß antibodies currently in clinical development for both AD and AMD by several large pharmaceutical companies. This is because those antibodies (e.g. solanezumab, bapineuzumab, gantenerumab, crenzeumab, RN6G and GSK33766A) are designed for a single purpose, namely to clear Aß, while none act on the important secondary neurotoxic mechanisms, such as oxidative stress that causes most of the damage from Aß. By contrast, CONJUMAB-A is empowered with a potent antioxidant. An important step in establishing proof-of-principle was the initial data generated through our collaboration with iNovacia to evaluate compounds synthesized by Lonza for Intellect. The data demonstrated the conjugation of the antioxidant molecule to an amino acid does not reduce its antioxidant activity. Pending adequate financial resources, these studies, which are almost complete, will allow us to select a drug candidate to take into development, providing the trigger for us to move forward with LONZA into an expanded manufacturing project, bringing us closer to the submission of an Investigational New Drug application."

https://globenewswire.com/news-release/2013/02/13/523315/10021734/en/Intellect-Neurosciences-Issues-Letter-to-Shareholders.html